GlassScriptPhysician profile
Andrew T Pham
NPI 1548838659
$1,142.15
in general payments reported to CMS, 2019-2025
14 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.30 · 2023: $125 · 2024: $626 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $187.19 | 2024 | Tavneos |
| Actelion Pharmaceuticals US, INC. | $144.36 | 2024 | Opsumit |
| Insmed, INC. | $125.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $123.09 | 2025 | Fasenra |
| Shionogi INC | $107.67 | 2024 | Fetroja |
| Merck Sharp & Dohme LLC | $105.12 | 2025 | Winrevair |
| Glaxosmithkline, LLC. | $103.66 | 2024 | Nucala |
| Bayer Healthcare Pharmaceuticals INC. | $81.26 | 2025 | |
| Alnylam Pharmaceuticals INC. | $37.74 | 2025 | Amvuttra |
| Karl Storz Endoscopy-America | $30.69 | 2024 | |
| Tempus Ai, INC | $27.64 | 2024 | |
| Ambu INC. | $24.82 | 2024 | |
| Aurinia Pharma U.S., INC. | $23.30 | 2022 | |
| La Jolla Pharmaceutical Company | $20.61 | 2025 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.